Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mizuho Financial Group Inc. Sponosred ADR (Japan) vs State Street SPDR S&P Biotech ETF — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.41 (market cap $132.18B), while State Street SPDR S&P Biotech ETF trades at $149.82 (market cap $10.08B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 13.1× State Street SPDR S&P Biotech ETF's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.7% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MFG | XBI | |
|---|---|---|
Market Cap | $132.18B | $10.08B |
Volume | 3,264,662 | 9,534,635 |
Sector | Financials | Broad Market / Factor |
52-Week High | $11.45 | $169.55 |
52-Week Low | $6.09 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $35.48T | — |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mizuho Financial Group Inc. Sponosred ADR (Japan)
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
